Palisade Bio, Inc.
PALI
$2.14
-$0.01-0.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 310.79% | 219.93% | 193.37% | 4.95% | -26.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 329.05% | 365.28% | 195.12% | -18.68% | -32.49% |
| Operating Income | -311.47% | -365.28% | -195.12% | 18.68% | 32.49% |
| Income Before Tax | -279.81% | -330.49% | -166.12% | 17.75% | 31.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -279.81% | -330.49% | -166.12% | 17.75% | 31.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -279.81% | -330.49% | -166.12% | 17.75% | 31.76% |
| EBIT | -311.47% | -365.28% | -195.12% | 18.68% | 32.49% |
| EBITDA | -311.59% | -365.45% | -195.12% | 18.68% | 32.49% |
| EPS Basic | 91.38% | 90.15% | 97.20% | 83.49% | 82.53% |
| Normalized Basic EPS | 91.37% | 90.16% | 97.20% | 83.49% | 82.53% |
| EPS Diluted | 91.38% | 90.15% | 97.20% | 83.49% | 82.53% |
| Normalized Diluted EPS | 91.37% | 90.16% | 97.20% | 83.49% | 82.53% |
| Average Basic Shares Outstanding | 4,306.36% | 4,272.01% | 9,412.43% | 398.13% | 290.49% |
| Average Diluted Shares Outstanding | 4,306.36% | 4,272.01% | 9,412.43% | 398.13% | 290.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |